Teva Pharmaceutical Industries Ltd. · NR3C1 · Small Molecule
beclometasone dipropionate is a small molecule developed by Teva Pharmaceutical Industries Ltd.. It is approved for therapeutic indications via inhaled.
| Brand Names | Aerobec, Junik, Ventolair |
| Company | Teva Pharmaceutical Industries Ltd. |
| Drug Class | Small Molecule |
| Molecular Target | NR3C1 |
| Route | Inhaled |
| Status | Approved |
beclometasone dipropionate acts on 1 molecular target:
| NR3C1 | nuclear receptor subfamily 3 group C member 1 (GR, GCCR) |
beclometasone dipropionate is developed for 1 unique indication across 1 therapeutic area.
| Therapeutic Area | Condition | Phase |
|---|---|---|
| Respiratory, thoracic and mediastinal disorders | Asthma | ✓ Approved |
Yokokawa Yuichi Y, Okumura Shunichi S, Yuza Yuki Y
Wang Si-Ning SN, Qiao Xiaojing X, Du Fangzhi F, Chen Jing J et al.
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by skin barrier dysfunction and immune dysregulation, which may influence topical drug penetration and therapeutic efficacy. This study evaluated a microneedle-assisted approach to enhance the cutaneous delivery of compound betamethasone in AD. Franz diffusion cell experiments demonstrated 3.29-fold and 4.67-fold increases in the 24-h cumulative permeation of betamethasone dipropionate (BDP) and betamethasone sodium phosphate (BSP), respectively, compared with passive application. In vivo fluorescence imaging showed greater penetration depth of fluorescein sodium following microneedle treatment, while histological examination revealed transient epidermal disruption. In a 2,4-dinitrochlorobenzene (DNCB)-induced AD mouse model, the combined treatment was associated with reduced epidermal thickening, mast cell accumulation, and serum IgE and IL-13 levels. In a pilot split-body clinical study involving 28 participants with mild-to-moderate AD, the microneedle + compound betamethasone-treated side showed greater improvements in Scoring Atopic Dermatitis (SCORAD) intensity and numeric rating scale (NRS) pruritus scores than the contralateral microneedle + saline control side after 7 days. No serious adverse events were observed during the study period. These findings demonstrate enhanced cutaneous permeation of compound betamethasone following microneedle-assisted application and provide preliminary evidence of therapeutic activity and short-term tolerability in AD.
Kopitovic Ivan I, Dimic-Janjic Sanja S, Stjepanovic Mihailo M, Hromis Sanja S et al.
Single-inhaler triple therapy (SITT) combines an inhaled corticosteroid (ICS; for example, fluticasone furoate, budesonide, or beclometasone dipropionate), a long-acting β2-agonist (LABA; for example, vilanterol or formoterol fumarate), and a long-acting muscarinic antagonist (LAMA; for example, umeclidinium or glycopyrronium bromide) in one device. Triple pharmacological therapy reduces exacerbations in selected patients with chronic obstructive pulmonary disease (COPD), but its effects on mortality and cardiovascular outcomes remain uncertain. This structured narrative review summarizes randomized trials, observational comparative-effectiveness studies, target trial emulations, systematic reviews, and health technology assessments published between 2015 and 2026. We grouped the evidence by comparator: LABA/LAMA, ICS/LABA, multiple-inhaler triple therapy (MITT), and ICS continuation versus withdrawal, because each comparison addresses a different clinical question. Pivotal trials and evidence syntheses consistently showed fewer moderate-to-severe exacerbations with triple therapy, with reported rate ratios of approximately 0.69-0.93. Mortality signals from IMPACT and ETHOS are clinically important, but previous ICS use and ICS withdrawal among participants assigned to ICS-free comparators make these findings difficult to interpret. Observational cardiovascular findings are also uncertain because residual confounding, treatment selection, exposure misclassification, outcome misclassification, and differences in baseline disease severity limit causal interpretation. Compared with MITT, the main advantages of SITT are simpler treatment and possible improvements in adherence and persistence, not greater pharmacological potency. Treatment decisions should consider exacerbation history, repeated blood eosinophil counts, pneumonia risk, cardiovascular disease, previous ICS exposure and response, inhaler technique, device suitability, and patient preference. Trials in patients with documented absence of previous ICS use and well-designed target trial emulations are needed to determine whether the observed mortality and cardiovascular associations are causal.
Petkov Rosen E RE, Kenderov Andrey N AN, Rodopska Neli L NL, Mekov Evgeni V EV et al.
The fixed triple beclomethasone dipropionate/formoterol fumarate/glycopyrronium (BDP/FF/GB) therapy is available in both pressurized metered-dose inhaler (pMDI) and dry powder inhaler (DPI) formulations for chronic obstructive pulmonary disease (COPD) treatment. While the pMDI form has been extensively investigated in pivotal trials and real-world studies, real-world data on the DPI (88/5/9 μg) formulation remain limited. The RESPONSE study assessed the real-world effectiveness of BDP/FF/GB inhalation powder in a cohort of moderate-to-severe COPD patients uncontrolled with dual combinations. This non-interventional, prospective, multicenter study was conducted across 21 Bulgarian sites. COPD patients (≥35 years) with persistent symptoms [COPD Assessment Tool (CAT) ≥10 and/or modified Medical Research Council (mMRC) ≥2] and moderate or severe pulmonary obstruction [30%≤ forced expiratory volume in 1 second as a percentage of predicted value (FEV1%) <80%] despite dual therapies were switched to BDP/FF/GB DPI and followed for 6 months. The primary endpoint was improvement in CAT scores. Secondary endpoints included lung function, treatment adherence, dyspnea and the percentage of patients achieving CAT score reduction ≥2 from baseline. A total of 363 patients completed the study. Mean CAT scores improved significantly from 23.0 at baseline to 16.9 (P<0.001), regardless of prior dual therapy or inhaler type. Mean (± SD) FEV1% increased from 47.6%±11.9% to 53.2%±15.75% (P<0.001). Treatment adherence and dyspnea also showed significant improvement. Notably, 87.9% of participants achieved a CAT score reduction ≥2 points. The RESPONSE study showed that switching to BDP/FF/GB DPI was associated with clinically meaningful improvements in symptoms, lung function, and adherence in COPD patients inadequately controlled on dual therapy, supporting its role as a practical escalation option in routine care.
Won Yumi Y, Lee Jungsoo J, Kim Hoonsoo H, Ko Hyunchang H et al.
Topical corticosteroids are acknowledged as the first-line treatment for pediatric alopecia areata. There are cases that are recalcitrant to topical corticosteroid application. The objective was to evaluate the efficacy of calcipotriol/betamethasone ointment in pediatric alopecia areata. In a 12-week retrospective study, 40 patients under 10 years old with alopecia areata were included. The patients were treated with a topical ointment combining 0.005% calcipotriol and betamethasone dipropionate once daily. The efficacy was monitored through changes in Severity of Alopecia Tool (SALT) scores. The 40 patients, with a mean age of 4.1±2.1 years, were categorized by their SALT scores into two groups: those above and below 50. Patients with SALT scores over 50 showed hair regrowth in 7.44±4.44 weeks, while those with SALT scores under 50 showed regrowth in 5.71±2.58 weeks. After 12 weeks, 80.0% of the patients showed hair regrowth and 20.0% of patients showed no response or worsening. Only minor adverse events were documented during follow-up. Calcipotriol/betamethasone ointment may represent a useful topical option for pediatric alopecia areata.
Rogliani Paola P, Brusselle Guy G, Stolz Daiana D, Piraino Alessio A et al.
The optimal timing for escalation to triple therapy in chronic obstructive pulmonary disease (COPD) remains undefined, often resulting in delayed treatment. Consequently, evidence on the effectiveness of early initiation is limited. This subgroup analysis used pooled patient-level data from six observational studies to evaluate the real-world effectiveness of beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide single-inhaler triple therapy (SITT) in COPD according to disease duration. Patients were stratified into three subgroups: ≤48 months (short), 49-96 months (intermediate), and ≥97 months (long-standing). Outcomes assessed at 3, 6, and 12 months post-SITT initiation included mean number of exacerbations, proportion of patients experiencing ≥1 exacerbation, and proportion achieving disease stability and control. Mean number of exacerbations decreased from the year prior to SITT initiation at all post-treatment time points across all subgroups, with the largest reductions observed in short disease patients, particularly at 12 months. Similarly, the proportion of patients experiencing ≥1 exacerbation decreased in all subgroups, with the lowest proportions observed in short disease patients. No differences between subgroups were observed at 3 and 6 months in the proportion of patients achieving disease stability and control; conversely, at 12 months the short disease subgroup showed significantly higher rates of disease stability and control compared with longer disease duration subgroups, suggesting that earlier SITT initiation may provide more sustained benefits. Early escalation to SITT in COPD may result in more durable sustained clinical benefits compared with later intervention, reducing exacerbations and maintaining disease stability and control up to 12 months.
+3766 more articles available with a free account
Sign up free to view all articles →